Immune pathogenesis and treatment of multifocal motor neuropathy

Journal of Clinical Immunology

Volumn 33, Issue SUPPL.1, 2013, Pages

  Vlam, Lotte ^a   Van Den Berg, Leonard H ^a   Cats, Elisabeth A ^a   Piepers, Sanne ^a   Van Der Pol, W Ludo ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

anti GM1 antibodies; immune pathogenesis; immunotherapy; intravenous immunoglobulin; Multifocal motor neuropathy

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOPHOSPHAMIDE; ECULIZUMAB; GANGLIOSIDE GM1 ANTIBODY; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB;

ACUTE MOTOR AXONAL NEUROPATHY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; AUTOIMMUNITY; COMPLEMENT ACTIVATION; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GENE; GUILLAIN BARRE SYNDROME; HLA DRB1 GENE; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOGENETICS; IMMUNOPATHOLOGY; LYMPHOCYTE PROLIFERATION; MOTOR NEUROPATHY; MUSCLE STRENGTH; MUSCLE WEAKNESS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW;

AUTOANTIBODIES; AUTOIMMUNITY; G(M1) GANGLIOSIDE; HUMANS; POLYNEUROPATHIES;

EID: 84872595711     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9779-8     Document Type: Review

References (26)

1. Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48-58.
2. Cats EA, van der Pol WL, Piepers S, Franssen H, Jacobs BC, van den Berg-Vos RM, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75(9):818-25.
3. Van Asseldonk JT, Van den Berg LH, Kalmijn S, Van den Berg-Vos RM, Polman CH, Wokke JH, et al. Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2006;77(6):743-7. (Pubitemid 43837201)
4. Rojas-Garcia R, Tizzano E, Cusco I, Gallardo E, Barcelo MJ, de Andres I, et al. The absence of survival motor neuron 2 gene may play a role in multifocal motor neuropathy. Neurology. 2002;59(7):1112-3.
5. Cats EA, Jacobs BC, Yuki N, Tio-Gillen AP, Piepers S, Franssen H, et al. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology. 2010;75(22):1961-7.
6. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125(Pt 12):2591-625. (Pubitemid 35423511)
7. Susuki K, Baba H, Tohyama K, Kanai K, Kuwabara S, Hirata K, et al. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia. 2007;55(7):746-57. (Pubitemid 46663027)
8. Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci. 2007;27(15):3956-67. (Pubitemid 46597169)
9. Piepers S, Jansen MD, Cats EA, van Sorge NM, van den Berg LH, van der Pol WL. IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN. J Neuroimmunol. 2010;229(1-2):256-62.
10. Yuki N, Watanabe H, Nakajima T, Spath PJ. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2011;82(1):87-91.
11. Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N. Conduction block in acute motor axonal neuropathy. Brain. 2010;133(10):2897-908.
12. Galban-Horcajoa F, Fitzpatricka AM, Huttona AJ, Dunna SM, Kalnab G, Brennana KM, et al. Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur J Neurol. Published online 22 jun 2012.
13. Pestronk A, Choksi R, Blume G, Lopate G. Multifocal motor neuropathy: serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to GM1 alone. Neurology. 1997;48:1104-6.
14. Pestronk A, Chuquilin M, Choksi R. Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside. J Neurol Neurosurg Psychiatry. 2010;81(7):726-30.
15. Terenghi F, Allaria S, Scarlato G, Nobile-Orazio E. Multifocal motor neuropathy and Campylobacter jejuni reactivity. Neurology. 2002;59(2):282-4. (Pubitemid 34779193)
16. Sutedja NA, Otten HG, Cats EA, Piepers S, Veldink JH, van der Pol WL, et al. Increased frequency of HLA-DRB1*15 in patients with multifocal motor neuropathy. Neurology. 2010;74(10):828-32.
17. Cats EA, Bertens AS, Veldink JH, van den Berg LH, van der Pol WL. Associated autoimmune diseases in patients with multifocal motor neuropathy and their family members. J Neurol. 2011 Nov 23. [Epub ahead of print]
18. Vlam L, Cats EA, Seelen M, van Vught PW, van den Berg LH, van der Pol WL. Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes. J Peripher Nerv Syst. 2011;16(3):175-9.
19. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol. 2009;16(5):631-8.
20. Eftimov F, Van Schaik IN. Immunotherapy of multifocal motor neuropathy. Expert Opin Biol Ther. 2011;11(3):329-42.
21. Piepers S, Van den Berg-Vos R, Van der Pol WL, Franssen H, Wokke J, Van den Berg L. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain. 2007;130(Pt 8):2004-10. (Pubitemid 47236626)
22. Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol. 2009;66(5):597-603.
23. Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011;16(2):84-91.
24. Qu H, Ricklin D, Lambris JD. Recent developments in low molecular weight complement inhibitors. Mol Immunol. 2009;47(2-3):185-95.
25. Phongsisay V, Susuki K, Matsuno K, Yamahashi T, Okamoto S, Funakoshi K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol. 2008;205(1-2):101-4.
26. Chaudhry V, Cornblath DR. An open-label trial of rituximab (Rituxan(R)) in multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15(3):196-201.